Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease

Bibliography

• Neurath MF, Finotto S. The many roads to inflammatory bowel diseases. Immunity 2006;25(2):189-91
   PubMed Web of Science ®Google Scholar
• Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006;3(7):390-407
   PubMedGoogle Scholar
• Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117(3):514-21
   PubMed Web of Science ®Google Scholar
• Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl 2):1-5
   PubMed Web of Science ®Google Scholar
• Subramanian S, Campbell BJ, Rhodes JM. Bacteria in the pathogenesis of inflammatory bowel disease. Curr Opin Infect Dis 2006;19(5):475-84
   PubMed Web of Science ®Google Scholar
• Sansonetti PJ, Di Santo JP. Debugging how bacteria manipulate the immune response. Immunity 2007;26(2):149-61
   PubMed Web of Science ®Google Scholar
• Egert M, de Graaf AA, Smidt H, et al. Beyond diversity: functional microbiomics of the human colon. Trends Microbiol 2006;14(2):86-91
   PubMed Web of Science ®Google Scholar
• Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361(9356):512-9
   PubMed Web of Science ®Google Scholar
• Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005;308(5728):1635-8
   PubMed Web of Science ®Google Scholar
• Macfarlane S, Hopkins MJ, Macfarlane GT. Bacterial growth and metabolism on surfaces in the large intestine. Microb Ecol Health Dis 2000;12(1):64-72
   Google Scholar
• Macfarlane S, Furrie E, Cummings JH, Macfarlane GT. Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clin Infect Dis 2004;38(12):1690-9
   PubMed Web of Science ®Google Scholar
• Bibiloni R, Mangold M, Madsen KL, et al. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol 2006;55(Pt 8):1141-9
   PubMed Web of Science ®Google Scholar
• Prindiville T, Cantrell M, Wilson KH. Ribosomal DNA sequence analysis of mucosa-associated bacteria in Crohn's disease. Inflamm Bowel Dis 2004;10(6):824-33
   PubMed Web of Science ®Google Scholar
• Seksik P, Sokol H, Lepage P, et al. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther 2006;24(Suppl 3):11-8
   PubMed Web of Science ®Google Scholar
• Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126(6):1620-33
   PubMed Web of Science ®Google Scholar
• Schultz M, Sartor RB. Probiotics and inflammatory bowel diseases. Am J Gastroenterol 2000;95(1 Suppl):S19-21
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Campieri M. Probiotics and antibiotics in inflammatory bowel disease. Curr Opin Gastroenterol 2001;17(4):331-5
   PubMed Web of Science ®Google Scholar
• Janowitz HD, Croen EC, Sachar DB. The role of the fecal stream in Crohn's disease: an historical and analytic review. Inflamm Bowel Dis 1998;4(1):29-39
   PubMed Web of Science ®Google Scholar
• D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114(2):262-7
   PubMed Web of Science ®Google Scholar
• Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102(3):448-55
   PubMed Web of Science ®Google Scholar
• Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005;54(8):1182-93
   PubMed Web of Science ®Google Scholar
• Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 2005;206:277-95
   PubMed Web of Science ®Google Scholar
• Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68(12):7010-7
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Kweon MN, Kuwata H, et al. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest 2003;111(9):1297-308
   PubMed Web of Science ®Google Scholar
• Bihl F, Salez L, Beaubier M, et al. Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J Immunol 2003;170(12):6141-50
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118(2):229-41
   PubMed Web of Science ®Google Scholar
• Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;113(9):1296-306
   PubMed Web of Science ®Google Scholar
• Gewirtz AT, Vijay-Kumar M, Brant SR, et al. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2006;290(6):G1157-63
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411(6837):603-6
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411(6837):599-603
   PubMed Web of Science ®Google Scholar
• Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003;3(5):371-82
   PubMed Web of Science ®Google Scholar
• Eckmann L, Karin M. NOD2 and Crohn's disease: loss or gain of function? Immunity 2005;22(6):661-7
   PubMed Web of Science ®Google Scholar
• Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006;6(1):9-20
   PubMed Web of Science ®Google Scholar
• Ouyang Q, Tandon R, Goh KL, et al. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol 2005;21(4):408-13
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124(4):993-1000
   PubMed Web of Science ®Google Scholar
• Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 2003;15(6):627-34
   PubMed Web of Science ®Google Scholar
• Buning C, Genschel J, Buhner S, et al. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 2004;19(10):1073-8
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Lammers KM, et al. Antimicrobials in the management of inflammatory bowel disease. Digestion 2006;73(Suppl 1):77-85
   PubMed Web of Science ®Google Scholar
• Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91(2):328-32
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108(6):1617-21
   PubMed Web of Science ®Google Scholar
• Shanahan F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005;288(3):G417-21
   Web of Science ®Google Scholar
• Salminen S, Bouley C, Boutron-Ruault MC, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998;80(Suppl 1):S147-71
   PubMed Web of Science ®Google Scholar
• Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003;16(4):658-72
   PubMed Web of Science ®Google Scholar
• O'Sullivan GC, Kelly P, O'Halloran S, et al. Probiotics: an emerging therapy. Curr Pharm Des 2005;11(1):3-10
   PubMed Web of Science ®Google Scholar
• Ewaschuk JB, Tejpar QZ, Soo I, et al. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr Gastroenterol Rep 2006;8(6):486-98
   PubMedGoogle Scholar
• Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 2007;115(1):1-11
   PubMed Web of Science ®Google Scholar
• Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004;126(5):1358-73
   PubMed Web of Science ®Google Scholar
• Otte JM, Podolsky DK. Functional modulation of enterocytes by Gram-positive and Gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004;286(4):G613-26
   PubMed Web of Science ®Google Scholar
• Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121(3):580-91
   PubMed Web of Science ®Google Scholar
• Shibolet O, Karmeli F, Eliakim R, et al. Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 2002;8(6):399-406
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126(2):520-8
   PubMed Web of Science ®Google Scholar
• Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100(7):1539-46
   PubMed Web of Science ®Google Scholar
• Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13(8):1103-8
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119(2):305-9
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124(5):1202-9
   PubMed Web of Science ®Google Scholar
• Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53(1):108-14
   PubMed Web of Science ®Google Scholar
• Kuhbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006;55(6):833-41
   PubMed Web of Science ®Google Scholar
• Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology 2000;118:A781
   Web of Science ®Google Scholar
• Matsumoto S, Watanabe N, Imaoka A, Okabe Y. Preventive effects of Bifidobacterium- and Lactobacillus-fermented milk on the development of inflammatory bowel disease in senescence-accelerated mouse P1/Yit strain mice. Digestion 2001;64(2):92-9
   PubMed Web of Science ®Google Scholar
• Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004;20(10):1133-41
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22(1):56-63
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Wehkamp K, et al. NF-κB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004;72(10):5750-8
   PubMed Web of Science ®Google Scholar
• Boudeau J, Glasser AL, Julien S, et al. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003;18(1):45-56
   PubMed Web of Science ®Google Scholar
• Schultz M, Strauch UG, Linde HJ, et al. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004;11(2):372-8
   PubMedGoogle Scholar
• Kamada N, Inoue N, Hisamatsu T, et al. Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis 2005;11(5):455-63
   PubMed Web of Science ®Google Scholar
• Grabig A, Paclik D, Guzy C, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun 2006;74(7):4075-82
   PubMed Web of Science ®Google Scholar
• Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354(9179):635-9
   PubMed Web of Science ®Google Scholar
• Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53(11):1617-23
   PubMed Web of Science ®Google Scholar
• Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25(4):653-8
   PubMed Web of Science ®Google Scholar
• Elmer GW, McFarland LV. Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin North Am 2001;30(3):837-54
   PubMed Web of Science ®Google Scholar
• Dalmasso G, Cottrez F, Imbert V, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006;131(6):1812-25
   PubMed Web of Science ®Google Scholar
• Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15(6):697-8
   PubMed Web of Science ®Google Scholar
• Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45(7):1462-4
   PubMed Web of Science ®Google Scholar
• Zhang L, Li N, Caicedo R, Neu J. Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J Nutr 2005;135(7):1752-6
   PubMed Web of Science ®Google Scholar
• Dieleman LA, Goerres MS, Arends A, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003;52(3):370-6
   PubMed Web of Science ®Google Scholar
• Veltkamp C, Tonkonogy SL, Schultz M, Sartor RB. Lactobacillus plantarum is superior to Lactobacillus GG in preventing colitis in IL-10 deficient mice. Gastroenterology 1999;116(4):A838
   Google Scholar
• Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;23(11):1567-74
   PubMed Web of Science ®Google Scholar
• Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003;17(4):509-15
   PubMed Web of Science ®Google Scholar
• Gupta P, Andrew H, Kirschner BS, Guandalini S. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000;31(4):453-7
   PubMed Web of Science ®Google Scholar
• Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004;4:5. Published online 15 March 2004; doi: 10.1186/1471-230X-4-5
   PubMed Web of Science ®Google Scholar
• Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005;11(9):833-9
   PubMed Web of Science ®Google Scholar
• Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51(3):405-9
   PubMed Web of Science ®Google Scholar
• Corr SC, Li Y, Riedel CU, et al. From the Cover: Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 2007;104(18):7617-21
   PubMed Web of Science ®Google Scholar
• Shanahan F, Guarner F, Von Wright A, et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology 2006;130(Suppl 2):A-44
   PubMed Web of Science ®Google Scholar
• McCarthy J, O'Mahony L, Dunne C, et al. An open trial of a novel probiotic as an alternative to steroids in mild/moderately active Crohn's disease. Gut 2001;49(Suppl 3):A2447
   Google Scholar
• Vidal K, Donnet-Hughes A, Granato D. Lipoteichoic acids from Lactobacillus johnsonii strain La1 and Lactobacillus acidophilus strain La10 antagonize the responsiveness of human intestinal epithelial HT29 cells to lipopolysaccharide and gram-negative bacteria. Infect Immun 2002;70(4):2057-64
   PubMed Web of Science ®Google Scholar
• Haller D, Bode C, Hammes WP, et al. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 2000;47(1):79-87
   PubMed Web of Science ®Google Scholar
• Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006;55(6):842-7
   PubMed Web of Science ®Google Scholar
• Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 2007;13(2):135-42
   PubMed Web of Science ®Google Scholar
• Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289(5483):1352-5
   PubMed Web of Science ®Google Scholar
• Vandenbroucke K, Hans W, Van Huysse J, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004;127(2):502-13
   PubMed Web of Science ®Google Scholar
• Braat H, Rottiers P, Hommes DW, et al. A Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4(6):754-9
   PubMed Web of Science ®Google Scholar
• Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125(6):1401-12
   PubMed Web of Science ®Google Scholar
• Macfarlane S, Macfarlane GT, Cummings JH. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 2006;24(5):701-14
   PubMed Web of Science ®Google Scholar
• Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res 2005;49(6):601-8
   PubMed Web of Science ®Google Scholar
• Kleessen B, Hartmann L, Blaut M. Oligofructose and long-chain inulin: influence on the gut microbial ecology of rats associated with a human faecal flora. Br J Nutr 2001;86(2):291-300
   PubMed Web of Science ®Google Scholar
• Bovee-Oudenhoven IM, ten Bruggencate SJ, Lettink-Wissink ML, van der Meer R. Dietary fructo-oligosaccharides and lactulose inhibit intestinal colonisation but stimulate translocation of salmonella in rats. Gut 2003;52(11):1572-8
   PubMed Web of Science ®Google Scholar
• Campbell JM, Fahey GC Jr, Wolf BW. Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. J Nutr 1997;127(1):130-6
   PubMed Web of Science ®Google Scholar
• Cherbut C, Michel C, Lecannu G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J Nutr 2003;133(1):21-7
   PubMed Web of Science ®Google Scholar
• Moreau NM, Martin LJ, Toquet CS, et al. Restoration of the integrity of rat caeco-colonic mucosa by resistant starch, but not by fructo-oligosaccharides, in dextran sulfate sodium-induced experimental colitis. Br J Nutr 2003;90(1):75-85
   PubMed Web of Science ®Google Scholar
• Lindsay JO, Whelan K, Stagg AJ, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006;55(3):348-55
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Toyonaga A, Sata M. Intestinal microflora as a therapeutic target in inflammatory bowel disease. J Gastroenterol 2002;37(Suppl 14):73-7
   PubMedGoogle Scholar
• Kanauchi O, Nakamura T, Agata K, et al. Effects of germinated barley foodstuff on dextran sulfate sodium-induced colitis in rats. J Gastroenterol 1998;33(2):179-88
   PubMed Web of Science ®Google Scholar
• Fukuda M, Kanauchi O, Araki Y, et al. Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med 2002;9(1):65-70
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Saiki T, Kanauchi O, et al. Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study. Aliment Pharmacol Ther 1998;12(12):1225-30
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Iwanaga T, Mitsuyama K. Germinated barley foodstuff feeding. A novel neutraceutical therapeutic strategy for ulcerative colitis. Digestion 2001;63(Suppl 1):60-7
   PubMed Web of Science ®Google Scholar
• Hanai H, Kanauchi O, Mitsuyama K, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004;13(5):643-7
   PubMed Web of Science ®Google Scholar
• Marteau P, Flourie B, Cherbut C, et al. Digestibility and bulking effect of ispaghula husks in healthy humans. Gut 1994;35(12):1747-52
   PubMed Web of Science ®Google Scholar
• Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 1991;26(7):747-50
   PubMed Web of Science ®Google Scholar
• Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999;94(2):427-33
   PubMed Web of Science ®Google Scholar
• Hallert C, Bjorck I, Nyman M, et al. Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm Bowel Dis 2003;9(2):116-21
   PubMed Web of Science ®Google Scholar
• Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics – approaching a definition. Am J Clin Nutr 2001;73(2 Suppl):361S-364S
   PubMed Web of Science ®Google Scholar
• Bengmark S. Pre-, pro- and synbiotics. Curr Opin Clin Nutr Metab Care 2001;4(6):571-9
   PubMed Web of Science ®Google Scholar
• Haskey N, Dahl WJ. Synbiotic therapy: a promising new adjunctive therapy for ulcerative colitis. Nutr Rev 2006;64(3):132-8
   PubMed Web of Science ®Google Scholar
• Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54(2):242-9
   PubMed Web of Science ®Google Scholar
• Hoentjen F, Welling GW, Harmsen HJ, et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis 2005;11(11):977-85
   PubMed Web of Science ®Google Scholar